Shenzhen Ruide Biomedical

Shenzhen Ruide Biomedical is a clinical-stage biotechnology company specializing in the development of innovative peptide therapeutics for metabolic and endocrine disorders. The company leverages its proprietary long-acting peptide technology platform to design multi-target agonists, including dual and triple receptor agonists targeting GLP-1, GIP, and glucagon receptors. Its lead programs, such as RD-01 and RD-03, are aimed at addressing significant unmet needs in obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Ruide Biomedical is committed to improving patient outcomes through treatments that offer superior efficacy and more convenient dosing schedules through improved pharmacokinetic profiles.